🏆 Deal of the Month · September 2024
PanTera raised EUR 93 million in a Series A round in September 2024; the company's valuation was not disclosed. The round was led by EQT Life Sciences alongside a broad consortium of seven co-investors. The financing will support PanTera's build-out of commercial-scale production capacity for actinium-225 (Ac-225), a critical radioisotope used in targeted cancer therapy.
PanTera — key deal facts
| Company | PanTera |
| Founded | 2022 |
| Headquarters | Mol, Belgium |
| Amount raised | EUR 93m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | EQT Life Sciences, Eurazeo, Ion Beam Applications, Korys, Kurma Partners, Paladin, PMV, SFPIM |
| Sectors | Health Care |
Who invested in PanTera?
The round drew participation from EQT Life Sciences, Eurazeo, Ion Beam Applications, Korys, Kurma Partners, Paladin, PMV, and SFPIM. The investor mix is notable for combining dedicated life-sciences growth equity (EQT Life Sciences, Kurma Partners), generalist European growth funds (Eurazeo), a strategic industrial backer (Ion Beam Applications), and Belgian public and quasi-public investors (PMV, SFPIM, Korys), reflecting both commercial conviction and national strategic interest in securing domestic radioisotope supply.
What does PanTera do?
PanTera is a Belgian radiopharmaceutical company founded in 2022 as a joint venture between IBA (Ion Beam Applications) and the nuclear research centre SCK CEN. The company is headquartered in Mol, Belgium, where it is establishing a dedicated production facility for actinium-225 (Ac-225), a short-supply alpha-emitting isotope used as an active pharmaceutical ingredient in radiotheranostic cancer treatments. PanTera's platform spans the design, production, and marketing of Ac-225-based radiopharmaceutical solutions, targeting the growing clinical demand for targeted alpha therapy in oncology. CEO Sven van den Berghe leads the company with the stated mission of enabling widespread, reliable access to Ac-225 for personalised tumour therapy.
PanTera valuation & multiples
No multiples analysis is available for this transaction, as PanTera's valuation was not disclosed at the time of the Series A close. Once comparable public-market benchmarks become relevant, Health Care sector EV/Sales and EV/EBITDA reference ranges can be found on the Venionaire DealMatrix sector multiples pages.
Explore the benchmarks: Series A.
Frequently asked questions
How much did PanTera raise in its Series A?
PanTera raised EUR 93 million in its Series A round, closed in September 2024.
What is PanTera's valuation?
PanTera's valuation was not disclosed in connection with the Series A financing.
Who invested in PanTera?
The Series A was led by EQT Life Sciences and included Eurazeo, Ion Beam Applications, Korys, Kurma Partners, Paladin, PMV, and SFPIM as co-investors.
When was PanTera founded and where is it based?
PanTera was founded in 2022 and is headquartered in Mol, Belgium.
Source: original announcement — read the full report.